» Authors » Abhishek Kavati

Abhishek Kavati

Explore the profile of Abhishek Kavati including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 38
Citations 410
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Cho S, Bekaii-Saab T, Kavati A, Babajanyan S, Hocum B, Barzi A
Clin Colorectal Cancer . 2022 Oct; 21(4):277-284. PMID: 36216759
Background: Recent phase 2 trials have provided data supporting regorafenib dose optimization (ReDO) and trifluridine/tipiracil (TAS-102) with bevacizumab (TAS-BEV) as treatment options in refractory metastatic colorectal cancer (mCRC). Historically, regorafenib...
2.
Klink A, Kavati A, Gassama A, Kozlek T, Gajra A, Antoine R
Target Oncol . 2022 Sep; 17(5):549-561. PMID: 36089643
Background: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are present across various tumor types with an estimated overall prevalence of less than 1%. Tropomyosin receptor kinase inhibitors (TRKis) block the...
3.
Klink A, Kavati A, Gassama A, Kozlek T, Gajra A, Antoine R
Target Oncol . 2022 Jun; 17(3):321-328. PMID: 35716252
Background: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers with an estimated prevalence of less than 1% across all solid tumors. Tropomyosin receptor kinase inhibitors (TRKis) block the...
4.
Vaduganathan M, Fonarow G, Greene S, DeVore A, Kavati A, Sikirica S, et al.
JACC Heart Fail . 2020 May; 8(6):469-480. PMID: 32387066
Objectives: The purpose of this study was to characterize the clinical profile, treatment patterns, and clinical outcomes of patients with comorbid diabetes mellitus (DM) and heart failure with reduced ejection...
5.
Samsky M, Lin L, Greene S, Lippmann S, Peterson P, Heidenreich P, et al.
JAMA Cardiol . 2019 Nov; 5(3):292-299. PMID: 31734700
Importance: There are major gaps in use of guideline-directed medical therapy (GDMT) for patients with heart failure (HF). Patient-reported data outlining patient goals and preferences associated with GDMT are not...
6.
Kavati A, Zhdanava M, Ortiz B, Lecocq J, Schiffman B, Pilon D, et al.
Clin Ther . 2019 Sep; 41(10):1956-1971. PMID: 31563391
Purpose: Biomarkers, including blood eosinophils (EoS) and fractional exhaled nitric oxide (FeNO), may affect omalizumab outcomes in allergic asthma, but evidence in the literature remains mixed. This study assessed omalizumab...
7.
Sullivan P, Li Q, Bilir S, Dang J, Kavati A, Yang M, et al.
Curr Med Res Opin . 2019 Sep; 36(1):23-32. PMID: 31491337
Uncontrolled asthma is associated with considerable clinical burden and costs to payers and patients. US economic models evaluating biologics using data from clinical trials demonstrate high incremental cost-effectiveness ratios (ICERs),...
8.
Goldstein S, Eftekhari S, Mitchell L, Winders T, Kaufman L, Dudas D, et al.
Acta Derm Venereol . 2019 Aug; 99(12):1091-1098. PMID: 31396637
Chronic spontaneous urticaria is challenging to manage and substantially affects quality of life. This US, non-interventional qualitative study examined patients' clinical journeys and emotional burden from symptom onset through disease...
9.
Kavati A, Zhdanava M, Ortiz B, Lecocq J, Schiffman B, Pilon D, et al.
Allergy Asthma Proc . 2019 Jul; 40(5):321-328. PMID: 31345280
Although clinical trials documented omalizumab's efficacy in U.S. patients with chronic idiopathic urticaria (CIU), the real-world evidence on its long-term effectiveness is lacking. To assess omalizumab use and the long-term...
10.
Li P, Kavati A, Puckett J, Jahnke J, Busse P, Hanania N, et al.
J Allergy Clin Immunol Pract . 2019 Jul; 8(2):507-515.e10. PMID: 31336178
Background: Asthma in older adults is associated with high rates of morbidity and mortality; similarly, asthma can be severe enough among younger adults to warrant disability benefits. Reasons for poor...